{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["55(2)"],"submitter":["Macaluso FS"],"pubmed_abstract":["<h4>Background</h4>Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy.<h4>Aims</h4>To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).<h4>Results</h4>1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reporte"],"journal":["Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"],"pagination":["154-159"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9420701"],"repository":["biostudies-literature"],"pubmed_title":["Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study."],"pmcid":["PMC9420701"],"pubmed_authors":["Furfaro F","Saibeni S","Milla M","Rizzo G","O'Sed NP","Felice C","Spagnuolo R","Paba S","Riguccio G","Casa A","Todeschini A","Correale C","Conforti FS","Mulinacci G","Bodini G","Desideri F","Bezzio C","Facciotti F","De Bona M","Radice S","Ribaldone DG","Macaluso FS","Fiorino G","Caprioli F","Mannino M","Orlando A","Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)","Doldo P","Vigano C","Scardino G","Vernero M","Fantini MC","Principi M","Amato A","Castiglione F","Calabrese G","Rizzuto G","Contaldo A","Nardone OM","Renna S","Demarzo MG","Ascolani M","Olmo O","Comberlato M","Dragoni G"],"additional_accession":[]},"is_claimable":false,"name":"Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.","description":"<h4>Background</h4>Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy.<h4>Aims</h4>To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).<h4>Results</h4>1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reporte","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-18T18:41:53.781Z","creation":"2025-02-19T03:29:03.069Z"},"accession":"S-EPMC9420701","cross_references":{"pubmed":["36127228"],"doi":["10.1016/j.dld.2022.08.027"]}}